To learn more about the enzymes involved in protein catabolism in skeletal and cardiac muscle and to identify selective inhibitors of this process, we studied the effects of proteinase inhibitors on protein turnover in isolated muscles and on proteolytic activities in muscle homogenates. Chymostatin (204uM) decreased protein breakdown by 20-40% in leg muscles from normal rodents and also in denervated and dystrophic muscles. These results are similar to our previous findings with leupeptin. The related inhibitors pepstatin, bestatin, and elastatinal did not decrease protein breakdown; antipain slowed this process in rat hind-limb muscles but not in diaphragm. Chymostatin did not decrease protein synthesis and thus probably retards proteolysis by a specific effect on cell proteinase(s). In homogenates of rat muscle, chymostatin, in common with leupeptin and antipain, inhibits the lysosomal proteinase cathepsin B, and the soluble Ca2+-activated proteinase. In addition, chymostatin, but not leupeptin, inhibits the chymotrypsin-like proteinase apparent in muscle homogenates. In muscles depleted of most of this activity by treatment with the mast-cell-degranulating agent 48/80, chymostatin still decreased protein breakdown. Therefore inhibition of this alkaline activity probably does not account for the decrease in protein breakdown. These results are consistent with a lysosomal site of action for chymostatin. Because of its lack of toxicity, chymostatin may be useful in in decreasing muscle atrophy in vivo.
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The proteins of muscle, in common with those of other tissues, undergo constant degradation and replacement (Schimke, 1970; Goldberg & Dice, 1974) . Changes in the rate of protein breakdown may contribute to normal muscle growth and the atrophy resulting from denervation, dystrophy and thyrotoxicosis (Goldspink, 1976; Goldspink & Goldspink, 1977; Goldberg et al., 1977) . Our knowledge of the factors influencing the rates of this process exceeds our understanding of its mechanism. Muscle contains many proteinases, both lysosomal and non-lysosomal, that could degrade cell protein in vivo (Pennington, 1977; Bird, 1975) . Both lysosomal and non-lysosomal proteinases seem to participate in breakdown of proteins in other cells (Knowles & Ballard, 1976; Hopgood et al., 1977; Etlinger & Goldberg, 1977; Neff et al., 1979) . However, in muscle the role of any given proteinase or organelle in the breakdown of average cell protein is unknown.
One approach to identification of the enzymes responsible for intracellular protein catabolism uses proteinase inhibitors of restricted specificity as 213 maintaining tissues in vitro and perhaps probes. For example, leupeptin, a peptide-aldehyde produced by actinomycetes that inhibits the lysosomal proteinase cathepsin B in intact muscles, slows proteolysis in isolated muscles (Libby & Goldberg, 1978) . The present study investigates the effects of the related proteinase inhibitor chymostatin on proteolysis in intact muscles and on proteinases in muscle homogenates. One goal of the present study was to identify additional agents that can inhibit protein breakdown in intact cells without producing toxic effects. Such compounds might be useful in retarding muscle atrophy in vivo and in helping to maintain tissues in culture. In fact, when cultured with leupeptin, dystrophic muscle cells appear to degenerate more slowly (McGowan et al., 1976; Stracher et al., 1978) , and foetal mouse hearts undergo atrophy to a lesser extent (Libby et al., 1979) .
Materials and Methods
The antibiotic proteinase inhibitors used in the present studies were the gifts of Professor H. (Umbreit et al., 1964) buffer equilibrated with 02/CO2 (19: 1), supplemented with glucose (10mM), insulin (0.1unit/ml) and in some cases amino acids at five times their normal rat plasma concentration (Fulks et al., 1975) . Under these conditions, rates of protein synthesis and degradation are constant for the period of study (Fulks et al., 1975) . Rates of protein breakdown were determined by measuring the net release of tyrosine from tissue protein with a fluorimetric assay (Fulks et al., 1975; Waalkes & Udenfriend, 1957) . This amino acid is neither synthesized nor degraded in muscle cells. Chymostatin cross-reacted weakly with tyrosine in this assay, and the fluorescence due to chymostatin was determined by blanks in each experiment and was subtracted from values reported. To measure protein degradation as an isolated process, we included cycloheximide (0.5 mM) in the medium to block protein synthesis. Net protein breakdown (i.e. the rate of protein degradation minus the rate of protein synthesis) was measured by tyrosine release in the absence of cycloheximide. These studies compared data obtained from five to seven paired contralateral muscles or from portions of the same atrium or diaphragm taken from littermate animals and incubated in parallel. Data obtained in this way showed much less variation than comparisons between groups of animals studied on different days. For reasons that are still unclear, rat muscles show significant day-to-day variations in rates of protein breakdown (Fulks et al., 1975 (Li et al., 1973; McKee et al., 1978) . Radioactivity was measured by liquid-scintillation spectroscopy with an automatic external standard to correct for quenching.
Preparation of muscle extracts and enzyme preparations Crude homogenates of mixed hind-limb muscle of rats were prepared by washing the freshly excised tissues with NaCl solution (154mM), placing them in buffer and disrupting them with four 30s bursts of a Teckmar homogenizer at 70% full speed. The homogenates were then dialysed at least overnight. These procedures were performed at 40C. For studies at acid pH, a phosphate/citrate buffer [100mM (K2HPO4, 76 mm; citric acid, 24 mM), pH 6] containing 2-mercaptoethanol (5 mM) or dithiothreitol (0.5 mM) and EDTA (1 mM) was used. For studies at alkaline pH, we used a potassium phosphate buffer (50mM, pH 7.8) containing KCI (100mM) . The Ca2+-activated proteinase was partially purified from rat skeletal muscle by the method of Dayton et al. (1976) . In some experiments, rats were treated with the mast-cell-degranulating agent 48/80 (Pastan & Almqvist, 1966) .
Enzyme andprotein assays
Hydrolysis by dialysed preparations of endogenous proteins and casein was measured at 370C by the production of primary amino groups soluble in trichloroacetic acid (10%, w/v) reactive with fluorescamine in borate/phosphate buffer (100mm, pH 9), with leucine as a standard (Bohlen et al., 1973) . Cathevsin B was measured by monitoring the hydrolysis of the substrate benzyloxycarbonylalanylarginylarginyl-4-methoxy-,J-naphthylamine fluorimetrically; the phosphate/citrate buffer described above was used (Smith & Van Frank, 1975) . The Ca2+-activated proteinase was assayed in Hepes [4 -(2 -hydroxyethyl) -1 -piperazine -ethanesulphonic acid] buffer (100mM, pH 7.5, with 100mM-KCI and 1 mM-NaN3 at 25 IC). The release of primary amines soluble in trichloroacetic acid (10%, w/v) was measured as described above during incubation with a-casein (20 mg/ml). Hydrolysis of acetyltyrosine ethyl ester was measured by the technique of Roberts (1958) . Protein was determined by the biuret reaction or by the method of Lowry et al. (1951) with bovine serum albumin as standard.
Results

Effects ofproteinase inhibitors on protein turnover in intact muscles
Chymostatin (20M) decreased the rate of protein breakdown in the red soleus muscle, the predominantly white extensor-digitorum-longus muscle, the diaphragm, which contains a mixture of fibre types, and in atrial strips (Table la) . The extent of the inhibition of proteolysis in the soleus muscle increased over the concentration range 0-20uM (Table lb) . In muscles incubated without cycloheximide, chymostatin also decreased net protein breakdown (i.e. the rate of protein breakdown minus the rate of protein synthesis; Table 2a ). To evaluate possible non-specific toxic effects of chymostatin, we measured directly the rates of protein synthesis in rat hind-limb muscles incubated with this agent. Chymostatin did not alter the rate of ['4C]phenylalanine incorporation (Table 2b ). Since this agent decreased protein breakdown without decreasing protein synthesis it probably acts specifically by inhibiting one or more cell proteinases.
Chymostatin also decreased protein breakdown in muscles atrophying due to section of the sciatic nerve compared with the contralateral muscle denervated at the same time (Table 3a ). The rate of protein breakdown increases in these muscles as a consequence of denervation (Goldspink, 1976) . In muscles of mice affected by genetic muscular dystrophy (dy2), this agent also inhibited protein breakdown (Table 3b ). In studies reported elsewhere, leupeptin produced comparable decreases in proteolysis in skeletal and atrial muscles from normal animals as well as denervated and dystrophic skeletal muscle (Libby & Goldberg, 1978) .
Antipain also decreased protein breakdown in rat hind-limb muscles. In the extensor-digitorumlongus muscle, antipain (20,M) decreased the rate of this process from 0.249 + 0.014 to 0.189+0.014nmol of tyrosine/2h per mg of tissue (Smith & Van Frank, 1975 (Barrett, 1977) . Leupeptin (30nM) inhibited this activity by 66% and virtually completely at 1 UM (Table 4) . Chymostatin, antipain and elastatinal inhibited cathepsin B in this cell-free preparation less effectively than leupeptin (Table 4) (Schwartz & Bird, 1977; Lenny et al., 1979) . Such inhibitors may prevent hydrolysis of protein substrates without interfering with cleavage of small synthetic substrates (Starkey & Barrett, 1973) .
A Ca2+-activated proteinase exists in muscle that catalyses removal of the Z-disc from the sarcomere in vitro (Reddy et al., 1975; Dayton et al., 1976 ). An endogenous inhibitor also prevents assay of this enzyme in crude muscle homogenates, and no specific substrate for this enzyme is currently known (Dayton et al., 1976; Waxman & Krebs, 1978) . To determine whether chymostatin inhibits this activity, we partially purified the enzyme from rat skeletal muscle (Dayton et al., 1976) . Ca2+ and dithiothreitol enhanced, and iodoacetate inhibited, this activity (Table 5) , which thus resembled the enzyme found in muscles of other species. Both chymostatin (2pM) and leupeptin (2pM) inhibited most of this activity (Fig. 1) . Toyo-Oka et al. (1978) have since reported that antipain and leupeptin also inhibit the Ca2+-activated proteinase from bovine heart. Therefore this calcium-activated proteinase is another possible site of action of these agents.
Rat skeletal-muscle homogenates exhibit appreciable proteolytic activity at alkaline-pH values (Koszalka & Miller, 1960) . Several groups have proposed that this alkaline activity, which may consist of one or more enzymes, plays a role in breakdown of myofibrillar protein (Noguchi & Kandatsu, 1971; Mayer et al., 1974; Dahlmann & Reinauer, 1978) . The so-called 'group-specific proteinase' in skeletal muscle resembles this activity as well (Banno et al., 1975) . Leupeptin, antipain, Table 5 . Effect of modifiers on the Ca2+-activated proteinase ofrat skeletal muscle This activity was measured by monitoring hydrolysis of a-casein (20mg/ml) at pH 7.5 by a fraction prepared from rat skeletal muscle by differential centrifugation and isoelectric precipitation (Dayton et al., 1976 pepstatin and phosphoramidon had little or no effect on hydrolysis of endogenous proteins in skeletalmuscle homogenates at pH 7.8 (results not shown). However, chymostatin (3pM) inhibited alkaline autolysis of muscle by 60-80% (Fig. 2) . To define this activity further we tested its sensitivity to a number of other protease inhibitors of known specificity. Toluenesulphonyl (tosyl) (1 mM) inhibited most of this alkaline proteolysis (Fig. 2) . Therefore this activity probably contains a serine residue in its active site. The site-directed affinity inhibitor 1-chloro-4-phenyl-3-L-tosylamidobutan-2-one ('TPCK'; 1 mM) decreased alkaline autolysis more than 7-amino-I-chloro-3-L-tosylamidohepatan-2-one ('TLCK'; 10mM; Fig. 2 ). Thus this activity shows more affinity for aromatic than basic residues, a property shared by chymotrypsin. Soya-bean trypsin inhibitor (50,ug/ml) inhibited proteolysis by muscle homogenates at pH 7.8 as well (Fig. 2) . Muscle extracts also exhibited chymostatin-sensitive cleavage of acetyltyrosine ethyl ester, a chymotrypsin substrate (Table 6 ). These properties are similar to neutral-proteinase activity in rat muscle The fraction studied was prepared by differential centrifugation and isoelectric precipitation under the conditions used by Dayton et al. (1976) . The casein-hydrolytic activity in this fraction was activated by Ca2+ and by a thiol-reducing agent (Table  5 ). The concentration of chymostatin and leupeptin was 3pM. An independent experiment gave similar results.
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This chymotrypsin-like activity in muscle may occur predominantly in mast cells rather than in myocytes. Park et al. (1973) showed that treatment of rats with the mast-cell-degranulating agent 48/80 (a condensation product of N-methyl-p-methoxyphenethylamine with formaldehyde) substantially decreased this activity. We confirmed this result, and
showed that this treatment in vivo diminished casein hydrolysis at pH 7.8 by homogenates of both red and white skeletal muscle of rats (Table 6) . Furthermore, treatment with agent 48/80 in vivo decreased the chymostatin-sensitive alkaline autolytic and esterolytic activity in muscle homogenates (Table   6 ). This treatment did not, however, decrease the specific activity of the lysosomal proteinase cathepsin B (results not shown). We then tested whether chymostatin could still decrease protein breakdown in muscles from agent-48/80-treated animals. Despite marked depletion of chymostatin-sensitive proteinase (Table 6) , protein breakdown still occurred at normal rates and the inhibitor still decreased protein breakdown in the isolated muscles. For example, chymostatin (20pM) decreased this process in extensor-digitorum-longus muscle from agent-48/80-treated rats from 0.247+0.010 to 0.176+ 0.007nmol of tyrosine/2h per mg (data combined from 17 pairs of extensor-digitorum-longus muscle studied in three independent experiments; P<0.01). These effects are very similar to those observed in muscles of control rats (Table 1 ).
Discussion
One goal of the present study was to identify enzymes responsible for protein breakdown in mammalian muscle. We found that chymostatin inhibits this process without altering the rate of protein synthesis. Since this agent did not seem to be toxic, it probably decreased protein breakdown by inhibiting one or more cell proteinases. Both chymostatin and leupeptin inhibited the lysosomal proteinase cathepsin B in muscle extracts (Table 4 ). This result, and those of other studies, are consistent with a role for this or related lysosomal proteinases such as cathepsin L in protein breakdown in intact muscles (Libby & Goldberg, 1978; Kirschke et al., 1977) . Chymostatin, leupeptin and antipain also inhibited the Ca2+-activated proteinase found in rat skeletal muscle (Fig. 1; Toyo-Oka et al., 1978) . Inhibition of this enzyme may also contribute to the effects of these agents on protein breakdown in intact cells.
In other experiments in cultured embryonic chick muscle, we found that leupeptin, chymostatin and antipain inhibited degradation of a specific muscle protein, the acetylcholine receptor (Libby et al., 1980) . These effects of chymostatin and leupeptin were not additive, which indicates that these agents may act on the same enzyme or on enzymes in the same pathway. Observations in myotubes strongly suggested a lysosomal site of action of these inhibitors, since degradation of the acetylcholine receptor probably occurs in the structure (Devreotes & Fambrough, 1976; Libby et al., 1980) . Chymostatin, unlike leupeptin or antipain, is also a potent inhibitor of most of the alkaline proteolytic activity apparent in rat muscle homogenates. We considered the possibility that this agent might also decrease protein breakdown in the intact muscle by inhibiting this activity. Many investigators have characterized alkaline proteinase(s) in muscle (Koszalka & Miller, 1960; Noguchi & Kandatsu, 1971; Holmes et al., 1971; Mayer et al., 1974; Table 6 . Effect oftreatment in vivo with agent 48/80 on chymotrypsin-like activity in rat muscles Rats were treated with intraperitoneal injections of agent 48/80 in increasing doses over 5 days before the rats were killed (Pastan & Almqvist, 1966) . The muscles were then excised and homogenized. This homogenate was dialysed and the indicated assay performed was measured. Autolysis (hydrolysis of endogenous proteins) and acetyltyrosine ethyl ester hydrolysis were measured in Hepes buffer (pH 7.8, 20mM) , 1975; Dahlmann & Reinauer, 1978; Woodbury et al., 1978b; Pennington, 1977) . Several groups have suggested an important role for these alkaline activities in intracellular protein breakdown, since they have activity at physiological pH, and are found associated with myofibrils in muscle homogenates. However, there is increasing evidence that the chymotrypsin-like activity in muscle occurs in mast cells rather than myocytes. As shown by Park et al. (1973) and confirmed in the present experiments (Table 6 ), treatment of rats with an agent that discharges mast-cell granules lowered this activity. Immunofluorescent and biochemical data also support a mast-cell origin and localization of this enzyme (Woodbury et al., 1978a,b) . Isolated cardiac myocytes contain little of this enzyme (Clark et al., 1980) . We found that muscles largely depleted of this activity after treatment with agent 48/80 still exhibit decreased protein breakdown when treated with chymostatin. For example, in the extensor-digitorum-longus muscle depleted of 70% of its alkalineproteinase activity (Table 6) , chymostatin still decreased protein breakdown by about 30%, which is similar to the inhibition seen in muscles from control rats (Table 1) . One cannot exclude the possibility that a minor pool of chymostatin-sensitive alkaline proteinase could exist within the myocyte and play an important role in protein breakdown. However, the simplest interpretation of these various results (Table 6; Park et al., 1973; Woodbury et al., 1978a,b; Clark et al., 1980) would be that the muscle chymotrypsin-like activity does not contribute significantly to breakdown of average proteins in muscle, and that chymostatin, in common with leupeptin, decreases protein breakdown by inhibiting lysosomal enzyme(s) and/or the Ca2+-activated proteinase. Since chymostatin does not seem to damage muscles at concentrations that inhibit overall protein breakdown, it may be of value in future studies of the mechanism of this process in other tissues as well. For example, one could use this or related agents as a probe to study the pathway of degradation of specific proteins. Previous work has used related proteinase inhibitors to study the pathway of degradation of proteins with normal or abnormal structures (Knowles & Ballard, 1976; Hopgood et al., 1977; Neff et al., 1979) . Since chymostatin and leupeptin retard the breakdown of protein in muscles atrophying after denervation or as a result of genetic muscular dystrophy, further studies should evaluate their potential for slowing atrophy of muscles in vitro and in vivo.
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